EUCTR2005-006141-16-GB进行中（未招募）1 期
A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects with Coronary Artery Disease - OXBIO
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or Female, aged 18 years or above.
- •-Multivessel coronary artery disease scheduled to undergo coronary bypass surgery.
- •-Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
- •-Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Pregnant or breastfeeding at screening or planning to become pregnant (subject of partner) at any time during study.
- •-Prior clinical diagnosis of heart failure requiring diuretic treatment with evidence of severe left ventricular dysfunction.
- •-Acute coronary event (unstable angina requiring hospitalisation, myocardial infarction) within the last 4 weeks.
- •-Emergency CABG.
- •-Newly diagnosed diabetes mellitus (<1 month).
- •-Body weight >130 kg.
- •-Impaired renal function (plasma creatinine > 180 µmol/l).
- •-Elevated liver function tests (defined as a serum alanine transaminase (ALT) >50µmol/l (or > 2x normal) and/or AST > 2x normal).
- •-Pacemakers, implantable defibrillators or metal implants that are not compatible with MRI scanning.
- •-Subjects receiving experimental medications or participating in another study using an experimental drug or experimental procedure within 30 days of enrollment into this study.
- •-Subject is terminally ill or is inappropriate for placebo medication.
- •-Any other significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or may influence the result of the study, or the subject’s ability to participate in the study.
- •-Requirements for concomitant treatment with any drug known to inhibit folate metabolism (e.g., methotrexate).
- •-Concomitant treatment with levodopa.
- •-Concomitant treatment with any phosphodiesterase (PDE) 5 inhibitors (e.g., Viagra®, Cialis®, Levitra®, or RevatioTM) or any PDE 3 inhibitor (e.g., cilostazol, milrinone, or vesnarinone)
- •-Subjects previously randomised into this study or any other clinical trial involving 6R-BH4 treatment.
- •-Known allergy or hypersensitivity to any excipient of 6R-BH4.
研究者
相似试验
招募中
1 期
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)Pruritus associated with Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-505764-11-00Mirum Pharmaceuticals Inc.395
进行中（未招募）
1 期
A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary sclerosing cholangitisPruritus associated with Primary Sclerosing Cholangitis (PSC)MedDRA version: 20.1Level: LLTClassification code 10036732Term: Primary sclerosing cholangitisSystem Organ Class: 100000004871EUCTR2020-003027-41-DEMirum Pharmaceuticals, Inc.300
进行中（未招募）
1 期
A study to examine the effects of the LEPR Agonist Antibody REGN4461 in patients with Familial Partial LipodystrophyEUCTR2021-000138-33-ESRegeneron Pharmaceuticals, Inc.40
已完成
不适用
A Double-Blind, Placebo-Controlled Study for Effects of Daily Ingestion of Azuki (Vigna angularis) bean Polyphenol on Lipid Metabolism ImprovementHealthy adultsJPRN-UMIN000021975Hokkaido Information University40
已完成
不适用
A Double-Blind, Placebo-Controlled Study for Effects of Daily Oral Administration of "Dattan Soba Seikatsu" on Blood pressure and Blood flow improvement.Healthy adultsJPRN-UMIN000026254Hokkaido Information University46